DeepMed Research

ZYDUS THERAPEUTICS INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Evaluating Pharmacokinetic and Safety of Saroglitazar Magnesium 1 Mg When Dosed on Alternate Days in Subjects Having Moderate Hepatic Impairment with Cirrhosis Due to Cholestatic Liver Disease

Phase 1

Not yet recruiting

Conditions: Cholestatic Liver Disease

Interventions: Drug: Saroglitazar Magnesium 1 mg

First Posted Date: 2025-02-13

Last Posted Date: 2025-02-13

Lead Sponsor: Zydus Therapeutics Inc.

Target Recruit Count: 6

Registration Number: NCT06825559

Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis

Phase 3

Recruiting

Conditions: Primary Biliary Cholangitis

Interventions: Drug: Saroglitazar Magnesium 1 mg

First Posted Date: 2024-05-23

Last Posted Date: 2025-03-04

Lead Sponsor: Zydus Therapeutics Inc.

Target Recruit Count: 150

Registration Number: NCT06427395

Locations: 🇺🇸
Zydus US007, Birmingham, Alabama, United States
🇺🇸
Zydus US013, Los Angeles, California, United States
🇺🇸
Zydus US011, Pasadena, California, United States

and more 38 locations

Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US

Phase 2

Terminated

Conditions: Nonalcoholic Fatty Liver Disease

Interventions: Drug: Saroglitazar Magnesium 4 mg
Drug: Placebo

First Posted Date: 2022-01-27

Last Posted Date: 2024-12-02

Lead Sponsor: Zydus Therapeutics Inc.

Target Recruit Count: 160

Registration Number: NCT05211284

Locations: 🇺🇸
Zydus US002, Indianapolis, Indiana, United States
🇺🇸
Zydus US004, Birmingham, Alabama, United States
🇺🇸
Zydus US005, La Jolla, California, United States

and more 5 locations

Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis

Phase 2

Active, not recruiting

Conditions: Primary Biliary Cholangitis

Interventions: Drug: Saroglitazar Magnesium 1 mg
Drug: Placebo
Drug: Saroglitazar Magnesium 2 mg

First Posted Date: 2021-11-24

Last Posted Date: 2025-03-04

Lead Sponsor: Zydus Therapeutics Inc.

Target Recruit Count: 186

Registration Number: NCT05133336

Locations: 🇹🇷
Zydus TR010, Istanbul, Turkey
🇹🇷
Zydus TR003, Istanbul, Turkey
🇹🇷
Zydus TR001, Istanbul, Turkey

and more 54 locations

Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease

Phase 1

Recruiting

Conditions: Cholestatic Liver Disease
Hepatic Impairment
Cirrhosis

Interventions: Drug: Saroglitazar Magnesium 1 mg
Drug: Saroglitazar Magnesium 2 mg

First Posted Date: 2021-09-16

Last Posted Date: 2025-03-04

Lead Sponsor: Zydus Therapeutics Inc.

Target Recruit Count: 30

Registration Number: NCT05045482

Locations: 🇺🇸
Zydus US002, Indianapolis, Indiana, United States

Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis

Phase 2

Active, not recruiting

Conditions: Nonalcoholic Steatohepatitis
Fibrosis

Interventions: Drug: Saroglitazar Magnesium 4 mg
Drug: Placebo
Drug: Saroglitazar Magnesium 2 mg

First Posted Date: 2021-08-18

Last Posted Date: 2025-03-04

Lead Sponsor: Zydus Therapeutics Inc.

Target Recruit Count: 240

Registration Number: NCT05011305

Locations: 🇺🇸
Zydus US090, Long Beach, California, United States
🇺🇸
Zydus US040, Los Angeles, California, United States
🇺🇸
Zydus US059, Rancho Cucamonga, California, United States

and more 149 locations

Hepatic Impairment, Cholestatic Liver Disease, & NASH With Advanced Fibrosis & Normal Hepatic Function

Phase 1

Recruiting

Conditions: Hepatic Impairment

Interventions: Drug: Saroglitazar Magnesium 4 mg
Drug: Saroglitazar Magnesium 2 mg

First Posted Date: 2020-07-14

Last Posted Date: 2023-10-10

Lead Sponsor: Zydus Therapeutics Inc.

Target Recruit Count: 100

Registration Number: NCT04469920

Locations: 🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States
🇺🇸
American Research Corporation at Texas Liver Institute, San Antonio, Texas, United States

A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects With Severe Renal Impairment and Normal Renal Function

Phase 1

Recruiting

Conditions: Renal Impairment

Interventions: Drug: Saroglitazar magnesium

First Posted Date: 2020-06-25

Last Posted Date: 2024-05-13

Lead Sponsor: Zydus Therapeutics Inc.

Target Recruit Count: 32

Registration Number: NCT04446507

Locations: 🇺🇸
Zydus US003, DeLand, Florida, United States
🇺🇸
Zydus US001, San Antonio, Texas, United States

Study to Evaluate Absorption, Metabolism and Excretion of Single-dose [14C]-Saroglitazar in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Saroglitazar magnesium

First Posted Date: 2019-10-02

Last Posted Date: 2019-11-13

Lead Sponsor: Zydus Therapeutics Inc.

Target Recruit Count: 8

Registration Number: NCT04112446

Locations: 🇺🇸
Covance Clinical Research Unit Inc., Madison, Wisconsin, United States

A Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Saroglitazar magnesium 4mg
Drug: Moxifloxacin 400mg
Drug: Saroglitazar magnesium 20 mg
Drug: Placebos

First Posted Date: 2019-08-06

Last Posted Date: 2020-04-21

Lead Sponsor: Zydus Therapeutics Inc.

Target Recruit Count: 52

Registration Number: NCT04045769

Locations: 🇮🇳
Cliantha Research Limited, Ahmedabad, Gujarat, India

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy